Shockwave Medical has registered for an upcoming initial public offering worth $70 million, according to recently posted SEC filings. The Santa Clara, Calif.-based vascular tech developer is looking to list its common stock on the Nasdaq Global Market under the symbol “SWAV,” according to the filing. Net proceeds from the offering are slated to support […]
Shockwave Medical launches U.S. pivotal for coronary lithotripsy
Shockwave Medical said today that it launched a U.S. pivotal trial for its coronary lithotripsy device, which is designed to prepare heavily calcified coronary lesions for stenting. The technology uses sonic pressure waves to fracture intimal and medial calcium without damaging arterial tissue, Santa Clara, Calif.-based Shockwave said. Last April the Shockwave S4 catheter, designed to similarly treat […]
Abiomed puts $15m into Shockwave
Abiomed (NSDQ:ABMD) plans to invest $15 million in Shockwave Medical and collaborate on a training and education program in the U.S. and Germany, according to a newly-inked deal between the two companies. Shockwave’s intravascular lithotripsy technology uses sonic pressure waves to crack vascular calcium in the vessel wall, allowing arteries to expand under low pressure. The […]
Shockwave wins CE Mark for S4 peripheral lithotripsy catheter
Shockwave Medical said today it won CE Mark approval in the European Union for its Shockwave S4 peripheral intravascular lithotripsy catheter. The Shockwave S4 is a low-profile catheter designed to treat calcified lesions below-the-knee arteries, which can be challenging to access and treat, and are often associated with critical limb ischemia. The company’s Lithoplasty devices are designed […]
Shockwave Medical raises $35m for Lithoplasty devices
Shockwave Medical said today that it raised another $35 million for the Lithoplasty devices it’s commercializing to treat blocked arteries. Fremont, Calif.-based Shockwave said it plans to use the new funding, which was led by new backer Fidelity Management & Research, to commercialize its existing devices for treating coronary and peripheral vessels in the U.S. and Europe […]
Shockwave Medical touts Disrupt BTK lithoplasty system study results
Shockwave Medical today released results from the Disrupt below the knee study of its Shockwave Lithoplasty system designed to treat peripheral artery disease, touting low rates of residual stenosis and low vascular complications. Data from the study was presented at the annual Cardiovascular and Interventional Radiological Society of Europe congress in Copenhagen, Denmark. “Interventional procedures that […]
Shockwave wins CE Mark for coronary Lithoplasty device
Shockwave Medical said today that it won CE Mark approval in the European Union for its coronary Lithoplasty system. The therapy is designed to treat calcified coronary artery blockages with lithotripsy – sonic pressure waves that are traditionally used to treat patients with kidney stones. The approval was supported by clinical data from the Disrupt […]
Shockwave Medical picks up ex-HeartWare CEO Godshall | Personnel Moves – May 11, 2017
Shockwave Medical said today it tapped former HeartWare CEO Doug Godshall as its new prez & CEO. Godshall served as CEO of HeartWare for 10 years until the business was acquired by Medtronic (NYSE:MDT) for $1.1 billion last August, Fremont, Calif.-based Shockwave Medical said. Prior to his time at HeartWare, Godshall held various executive and leadership […]
Shockwave Medical launches lithoplasty trial
Shockwave Medical said today it enrolled the 1st patient in the Disrupt PAD III trial of its Lithoplasty system, aiming to explore the system’s effectiveness at treating heavily calcified lesions in the leg compared to traditional angioplasty. The company’s Lithoplasty device is designed to use intermittent lithotripsy pulses to disrupt superficial and deep vascular calcium and an angioplasty balloon to […]
Shockwave Medical raises $45m Series C for Lithoplasty device
Shockwave Medical said today that it raised a $45 million Series C round for the Lithoplasty device it developed to treat calcified vasular lesions. Fremont, Calif.-based Shockwave said Sectoral Asset Management led the round, joined by new backer T. Rowe Price and existing investors Sofinnova Partners, Venrock, RA Capital, Deerfield, Ally Bridge Group and others. Shockwave said it […]
Medtronic touts low CD-TLR rates, strong durability in 3-year In.Pact Admiral DCB study | VIVA 2016 Roundup
Medtronic (NYSE:MDT) this week released data from 2 clinical studies evaluating its In.Pact Admiral drug-coated balloon for treating claudication and restenosis, touting sustained durability at 3-years. Results were presented at the Vascular Interventional Advances 2016 conference in Las Vegas this week. Those of you who want strength without size, lean muscles, or if you’re cutting, http://topsteroidsforsale.com is relatively safe […]
MassDevice Network
@MassDevice
LinkedIn
YouTube